| Symbol | KOD |
|---|---|
| Name | KODIAK SCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 1250 PAGE MILL RD, PALO ALTO, CA 94304 |
| Telephone | 650-281-0850 |
| Fax | — |
| — | |
| Website | https://www.kodiak.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001468748 |
| Description | Kodiak Sciences Inc is is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. Additional info from NASDAQ: |
2026-05-15 09:01
New Form SCHEDULE 13G - Kodiak Sciences Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003206 <b>Size:</b> 15 KB
Read more
2026-05-07 20:00
(10% Negative) KODIAK SCIENCES INC. (KOD) Announces Delay in opportunities Trials for Kodiak Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more
2026-05-07 20:00
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Read more
2026-05-01 04:23
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Read more
2026-04-22 17:19
New Form DEFA14A - Kodiak Sciences Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170482 <b>Size:</b> 4 MB
Read more
2026-04-22 17:14
New Form DEF 14A - Kodiak Sciences Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170429 <b>Size:</b> 14 MB
Read more
2026-04-16 21:00
BORGESON JOHN A. 🟡 adjusted position in 0 shares (1 derivative) of Kodiak Sciences Inc. (KOD) at $1.04 Transaction Date: Apr 15, 2026 | Filing ID: 000004
Read more
2026-04-03 00:26
BORGESON JOHN A. 🟡 adjusted position in 30.0K shares (1 derivative) of Kodiak Sciences Inc. (KOD) at $41.77 ($1.3M) Transaction Date: Apr 02, 2026 | Filing ID: 000002
Read more
2026-04-02 20:23
📋 JOHN BORGESON (Officer) plans to sell 30K shares of KODIAK SCIENCES INC. (at $42.81 each, total $1.3M) Filed: Apr 02, 2026 | ID: 003206
Read more
2026-04-02 17:11
New Form SCHEDULE 13G - Kodiak Sciences Inc. <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0000902664-26-001849 <b>Size:</b> 17 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06990399 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in … | Phase3 | Macular Edema Secondary to Inflammation | Recruiting | 2025-07-30 | 2027-11-01 | ClinicalTrials.gov |
| NCT06996080 | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in … | Phase3 | Macular Edema Secondary to Inflammation | Recruiting | 2025-07-16 | 2027-08-01 | ClinicalTrials.gov |
| NCT06556368 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafu… | Phase3 | Wet Age-related Macular Degeneration | Active_Not_Recruiting | 2024-08-23 | 2027-08-01 | ClinicalTrials.gov |
| NCT06270836 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared Wit… | Phase3 | Diabetic Retinopathy | Completed | 2024-05-01 | 2026-02-13 | ClinicalTrials.gov |
| NCT05066230 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-prol… | Phase3 | Non-proliferative Diabetic Retinopathy | Terminated | 2021-09-07 | 2023-08-31 | ClinicalTrials.gov |
| NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared Wi… | Phase3 | Wet Age-related Macular Degeneration | Completed | 2021-06-23 | 2023-04-06 | ClinicalTrials.gov |
| NCT04611152 | A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to… | Phase3 | Diabetic Macular Edema | Terminated | 2020-09-30 | 2023-08-31 | ClinicalTrials.gov |
| NCT04603937 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to… | Phase3 | Diabetic Macular Edema | Terminated | 2020-09-30 | 2023-08-31 | ClinicalTrials.gov |
| NCT04592419 | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to… | Phase3 | Macular Edema | Completed | 2020-09-25 | 2023-01-19 | ClinicalTrials.gov |
| NCT04049266 | A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody B… | Phase2 | Wet Macular Degeneration | Terminated | 2019-10-08 | 2022-04-26 | ClinicalTrials.gov |
| NCT03790852 | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, T… | Phase1 | Wet Age-related Macular Degeneration | Terminated | 2018-12-26 | 2022-06-09 | ClinicalTrials.gov |
Total clinical trials: 11
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | COMPLETED | NCT06270836 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06990399 |
| KSI-301 | Other | Phase PHASE1 | Wet Age-related Macular Degeneration | TERMINATED | NCT03790852 |
| Sham Procedure | Procedure | Phase PHASE3 | Macular Edema | COMPLETED | NCT04592419 |
| Aflibercept | Other | Phase PHASE3 | Macular Edema | COMPLETED | NCT04592419 |
| KSI-301 | Other | Phase PHASE3 | Macular Edema | COMPLETED | NCT04592419 |
| Sham Procedure | Procedure | Phase PHASE3 | Wet Age-related Macular Degeneration | COMPLETED | NCT04964089 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | COMPLETED | NCT04964089 |
| KSI-301 | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | COMPLETED | NCT04964089 |
| Sham Procedure | Procedure | Phase PHASE2 | Wet Macular Degeneration | TERMINATED | NCT04049266 |
| Aflibercept | Other | Phase PHASE2 | Wet Macular Degeneration | TERMINATED | NCT04049266 |
| KSI-301 | Other | Phase PHASE2 | Wet Macular Degeneration | TERMINATED | NCT04049266 |
| Sham Procedure | Procedure | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04611152 |
| Aflibercept | Other | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04611152 |
| KSI-301 | Other | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04611152 |
| Sham Procedure | Procedure | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04603937 |
| Aflibercept | Other | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04603937 |
| KSI-301 | Other | Phase PHASE3 | Diabetic Macular Edema | TERMINATED | NCT04603937 |
| Sham injection | Other | Phase PHASE3 | Non-proliferative Diabetic Retinopathy | TERMINATED | NCT05066230 |
| KSI-301 | Other | Phase PHASE3 | Non-proliferative Diabetic Retinopathy | TERMINATED | NCT05066230 |
| Sham injection | Other | Phase PHASE3 | Diabetic Retinopathy | ACTIVE_NOT_RECRUITING | NCT06270836 |
| Tarcocimab | Other | Phase PHASE3 | Diabetic Retinopathy | ACTIVE_NOT_RECRUITING | NCT06270836 |
| Sham Comparator | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | Other | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Aflibercept | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tabirafusp tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | Other | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Sham Comparator | OTHER | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| KSI-101 | DRUG | Phase PHASE3 | Macular Edema Secondary to Inflammation | RECRUITING | NCT06996080 |
| Tabirafusp tedromer | DRUG | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab tedromer | DRUG | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| Tarcocimab | DRUG | Phase PHASE3 | Diabetic Retinopathy | ACTIVE_NOT_RECRUITING | NCT06270836 |
| Sham injection | OTHER | Phase PHASE3 | Diabetic Retinopathy | ACTIVE_NOT_RECRUITING | NCT06270836 |
| Sham Procedure | OTHER | Phase PHASE3 | Wet Age-related Macular Degeneration | COMPLETED | NCT04964089 |
| Aflibercept | DRUG | Phase PHASE3 | Wet Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06556368 |
| KSI-301 | DRUG | Phase PHASE3 | Non-proliferative Diabetic Retinopathy | TERMINATED | NCT05066230 |
Total products: 99